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PHA310 – Clinical Pharmacokinetics 
DURATION 
 
Reading Time: 10 minutes 
Writing Time: 180 minutes 
 
INSTRUCTIONS TO CANDIDATES 
 
The examination has 2 Sections (A and B): 
Section A contains Forty (40) Multiple Choice Questions.  Answer all questions on the College supplied 
Multiple Choice Answer Sheet.  Total marks allocated: Forty (40).  Suggested time allocation: One hour 
(60 minutes). 
 
Section B contains Six (6) Calculation Questions.  Answer all questions in the 20-page Booklet provided.  
Show all relevant steps in your calculations and include all relevant units in your answers.  Total marks 
allocated: One hundred (100). Suggested time allocation: Two hours (120) minutes. 
 
Total marks for this exam paper: 140 
 
EXAM CONDITIONS 
You may begin writing from the commencement of the examination session.  The reading time indicated above is 
provided as a guide only. 
This is a CLOSED BOOK examination 
Any non-programmable calculator is permitted 
No handwritten notes are permitted 
No dictionaries are permitted 
 
ADDITIONAL AUTHORISED MATERIALS EXAMINATION MATERIALS TO BE SUPPLIED 
 
No additional printed material is permitted 
 
 
1 x 20 Page Book 
1 x 5-Multiple Choice Answer Sheet 
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Total Marks for this section: 100 
Answer ALL Six (6) questions 
This section should be answered in the 20-page Answer Booklet provided. 
Marks for each question are indicated. 
Show all relevant steps in your calculations and include all relevant units in your answers. 
Suggested Time allocation for Section B:  120 min 
 
Question 1 (16 marks; Suggested time allocation 20 min) 
After 400mg of an antibiotic was administered intravenously as a single dose to Mrs L a plot of the 
plasma drug concentration-time profile on a semilog paper is linear with slope of -0.1 h-1 and y-intercept 
of 1 g/ml. 
a Calculate k, Vd, CLT, AUC and t½ of this antibiotic in Mrs L. 
 (8 marks) 
b What are the slope and y-intercept if the dose was 800 mg? 
 (2 marks) 
c Calculate the time required for the initial drug concentration to reduce to 0.25 g/ml after 
IV administration of the 400 mg dose. 
 (3 marks) 
d What is the minimum dose required to achieve plasma drug concentration above 1 g/ml 
for 6 hours after drug administration? 
 (3 marks) 
 
  
 Semester 1, 2018 FINAL EXAMINATION Page 4 of 7  
PHA310 – Clinical Pharmacokinetics 
 
THIS EXAMINATION PAPER AND SUPPLIED MATERIALS ARE NOT PERMITTED TO BE REMOVED FROM ANY EXAMINATION VENUE IN ANY 
CIRCUMSTANCE.  THIS EXAMINATION IS PRINTED DOUBLE-SIDED. 
 
Question 2 (10 marks; Suggested time allocation 12 min) 
Ms KY, a 60-year old, 60 kg female is admitted to the hospital due to acute pneumonia. She is receiving 
75 mg gentamicin as repeated IV infusions (for 1 hour) every 12 hours. Her serum creatinine is found to 
be 2.5 mg/dL. Assuming the clearance of the antibiotic is 7.2L/hr with an elimination half-life (t½) of 3 
hours: 
a Estimate the creatinine clearance in this patient. 
 (2 marks) 
b Calculate the plasma concentration of the antibiotic in Ms KY after the first IV infusion. 
 (2 marks) 
c Calculate Cmax, Cmin and Caverage of this antibiotic in Ms KY at steady-state. 




Question 3 (16 marks; Suggested time allocation 20 min) 
After a single IV bolus administration of 10mg of a drug, the following plasma concentrations were 
obtained. The terminal rate constant for the decline in drug concentration (λ) is 0.1h-1. Calculate the 
MRT, clearance and Vdss. 











 Semester 1, 2018 FINAL EXAMINATION Page 5 of 7  
PHA310 – Clinical Pharmacokinetics 
 
THIS EXAMINATION PAPER AND SUPPLIED MATERIALS ARE NOT PERMITTED TO BE REMOVED FROM ANY EXAMINATION VENUE IN ANY 
CIRCUMSTANCE.  THIS EXAMINATION IS PRINTED DOUBLE-SIDED. 
 
Question 4 (20 marks; Suggested time allocation 22 min) 





Drug conc in Urine 
(mg/mL) 
Cpt-mid (mg/L) 
0-2 125 1.776 15.9 
2-4 150 0.933 10.0 
4-6 175 0.504 6.3 
6-8 138 0.403 4.97 
8-10 163 0.215 2.51 
10-14 313 0.112 1.24 
 
a Estimate the biological half-life of this drug in this patient using urinary excretion data. 
   (8 marks) 
b Estimate the renal clearance of this drug in this patient.  
 (6 marks) 
c Calculate the fraction of the administered dose excreted unchanged in the urine from the 
available data. 
 (6 marks) 
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Question 5 (24 marks; Suggested time allocation 28 min) 
Mr Z received a single oral dose of 5 mg of a bronchodilator that is completely absorbed after oral 
administration (F = 1). The following plasma concentration time data were obtained: 
Time (hr) Plasma Drug 
Concentration (ng/mL) 
Time (hr) Plasma Drug 
Concentration (ng/mL) 
0 0.00 4.0 31.1 
0.2 10.0 6.0 18.6 
0.5 21.5 8.0 10.2 
1.0 33.4 10.0 5.44 
2.0 40.7 14.0 1.47 
3.0 37.6   
a Plot the plasma concentration-time curve (with proper labels) and determine the elimination 
rate constant (k), and half-life (t½) of this bronchodilator in Mr Z. 
 (8 marks) 
b Use the method of residuals to calculate the absorption rate constant (ka). 
 (8 marks) 
c What is the equation that describes the plasma concentration time profile of this drug in 
Mr Z after oral administration? 
 (4 marks) 
d Calculate the tmax and Cmax. 
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Question 6 (14 marks; Suggested time allocation 18 min) 
Ms SNI, a 32-year-old 75kg female has been taking an oral dose of 200mg phenytoin daily to control her 
simple partial seizures.  After one month of therapy, her average phenytoin plasma concentration was 
measured at only 5mg/L, which was insufficient to control her seizures. So her daily oral phenytoin dose 
was increased to 175 mg b.d. (i.e. twice daily).  Since starting this increased daily dose her average 
plasma phenytoin concentration was 21 mg/L.  Assuming that the volume of distribution of phenytoin is 
0.75 L/kg and the absolute bioavailability of oral phenytoin is 100% (i.e., F = 1): 
a Using the direct linear plot (Mullen Method – with proper labels), determine the Vmax and Km for 
phenytoin in this patient. 
       (8 marks) 
b Recommend a dosage regimen to maintain steady-state plasma phenytoin concentration around 
15mg/L (therapeutic range 10-20mg/L). 
       (2 marks) 
c What will be the half-life (t½) of phenytoin at steady-state if a dose of 175 mg every 12 
hours was given to Mrs SNI? 





End of Section B 
 
 
End of Exam Paper 
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Drug Absorption and Distribution 
𝑅𝑎𝑡𝑒 𝑜𝑓 𝑑𝑖𝑓𝑓𝑢𝑠𝑖𝑜𝑛 =
𝐷𝐾𝑆
ℎ
(𝐶𝑎𝑏𝑠 − 𝐶𝑝) 




𝑙𝑜𝑔𝑃 = 𝑙𝑜𝑔 [
𝐷𝑟𝑢𝑔 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑖𝑛 𝑛 − 𝑜𝑐𝑡𝑎𝑛𝑜𝑙
𝐷𝑟𝑢𝑔 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑖𝑛 𝑤𝑎𝑡𝑒𝑟
] 


















∙ (𝐶𝑠 − 𝐶𝑝) 













𝐿𝑜𝑎𝑑𝑖𝑛𝑔 𝑑𝑜𝑠𝑒 = 𝐶 ∙ 𝑉𝑑 
Drug Elimination 










𝑄𝐻 + 𝑓𝑢 ∙ 𝐶𝐿′𝑖𝑛𝑡
 









𝐸𝑙𝑖𝑚𝑖𝑛𝑎𝑡𝑖𝑜𝑛 𝑟𝑎𝑡𝑒 = 𝐶𝐿𝑜𝑟𝑔𝑎𝑛 ∙ 𝐶𝑝0 








= 𝑘𝑒 ∙ 𝐴 
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∆𝐴𝑒
∆𝑡
=  𝑘𝑒 ∙ 𝑉𝑑 ∙ 𝐶𝑝𝑡−𝑚𝑖𝑑 
Renal Clearance: 𝐶𝐿 = 𝑘𝑒 ∙ 𝑉𝑑 
First-order Elimination 
𝐶 = 𝐶0 ∙ 𝑒
−𝑘𝑡 
𝑙𝑛𝐶 = 𝑙𝑛𝐶0 − 𝑘𝑡 








































) (𝑡1 − 𝑡0) + (
𝐶1 + 𝐶2
2
) (𝑡2 − 𝑡1) + (
𝐶2 + 𝐶3
2























Drug Renal Excretion Rate Time Profile for Pharmacokinetic Calculations 
Renal excretion rate time profile: 
∆𝐴𝑒
∆𝑡
= 𝑘𝑒 ∙ 𝐴0 ∙ 𝑒
−𝑘𝑡 
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Constant Rate IV Infusion 


















) + 𝐶𝑝𝑥 ∙ 𝑒
−𝑘𝑡′ 
𝐶𝑝max 𝑠𝑠 =
𝐾0 ∙ (1 − 𝑒
−𝑘𝑡′)
𝑉𝑑 ∙ 𝑘 ∙ (1 − 𝑒−𝑘𝜏)
 











𝐶𝑝min 𝑠𝑠 = 𝐶𝑝max 𝑠𝑠 ∙ 𝑒
−𝑘𝜏 






















(1 − 𝑒−𝑘𝑡) 
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First-order absorption and elimination 
𝐶𝑝 =
𝐹 ∙ 𝐷𝑜𝑠𝑒 ∙ 𝑘𝑎
𝑉𝑑(𝑘𝑎 − 𝑘)
















𝐹 ∙ 𝐷𝑜𝑠𝑒 ∙ 𝑘𝑎
𝑉𝑑(𝑘𝑎 − 𝑘)
(𝑒−𝑘𝑡𝑚𝑎𝑥 − 𝑒−𝑘𝑎𝑡𝑚𝑎𝑥) 
𝑦 − 𝑖𝑛𝑡𝑒𝑟𝑐𝑒𝑝𝑡 =










With lag time t0 𝐶𝑝 =
𝐹∙𝐷𝑜𝑠𝑒∙𝑘𝑎
𝑉𝑑∙(𝑘𝑎−𝑘)
∙ (𝑒−𝑘(𝑡−𝑡0) − 𝑒−𝑘𝑎(𝑡−𝑡0)) 




𝐹 ∙ 𝐷𝑜𝑠𝑒 ∙ 𝑘𝑒 ∙ 𝑘𝑎
𝑘𝑎 − 𝑘
∙ (𝑒−𝑘𝑡 − 𝑒−𝑘𝑎𝑡) 
𝐴𝑒 =
𝐹 ∙ 𝐷𝑜𝑠𝑒 ∙ 𝑘𝑒 ∙ 𝑘𝑎














∙ 𝐹 ∙ 𝐷𝑜𝑠𝑒 
Residuals Method or Wagner-Nelson Method to Determine ka 
𝑅𝑒𝑠𝑖𝑑𝑢𝑎𝑙𝑠 =
𝐹 ∙ 𝐷𝑜𝑠𝑒 ∙ 𝑘𝑎
𝑉𝑑 ∙ (𝑘𝑎 − 𝑘)
∙ 𝑒−𝑘𝑡 − 𝐶𝑝 






















(𝑒−𝑘𝑡 − 𝑒−𝑘(𝑚)𝑡) 
𝐶𝑝(𝑚) =
𝑓𝑚 ∙ 𝑘 ∙ 𝐷
𝑉𝑑(𝑚)(𝑘(𝑚) − 𝑘)
(𝑒−𝑘𝑡 − 𝑒−𝑘(𝑚)𝑡) 
(fm = fraction of administered dose being metabolised) 
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(𝐾𝑚 + 𝐶𝑝) 
Multicompartment Models 
𝐶𝑝 =
𝐷 ∙ (𝛼 − 𝑘21)
𝑉𝑐 ∙ (𝛼 − 𝛽)
∙ 𝑒−𝛼𝑡 +
𝐷 ∙ (𝑘21 − 𝛽)
𝑉𝑐(𝛼 − 𝛽)
∙ 𝑒−𝛽𝑡 
𝐶𝑝 = 𝐴 ∙ 𝑒
−𝛼𝑡 + 𝐵 ∙ 𝑒−𝛽𝑡 
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𝐴 =
𝐷 ∙ (𝛼 − 𝑘21)
𝑉𝑐 ∙ (𝛼 − 𝛽)
 
𝐵 =
𝐷 ∙ (𝑘21 − 𝛽)
𝑉𝑐(𝛼 − 𝛽)
 
𝛼 + 𝛽 = 𝑘12 + 𝑘21 + 𝑘10 













































𝑘12 = (𝛼 + 𝛽) − (𝑘21 + 𝑘10) 
𝑉𝑑 𝑠𝑠 =





= 𝑉𝑐 + 𝑉𝑐 ∙
𝑘12
𝑘21












𝑘𝑎 ∙ 𝐹 ∙ 𝐷
𝑉𝑐
) [
(𝑘21 − 𝛼) ∙ 𝑒
−𝛼𝑡
(𝛽 − 𝛼) ∙ (𝑘𝑎 − 𝛼)
+
(𝑘21 − 𝛽) ∙ 𝑒
−𝛽𝑡
(𝑘𝑎 − 𝛽) ∙ (𝛼 − 𝛽)
+
(𝑘21 − 𝑘𝑎) ∙ 𝑒
−𝑘𝑎𝑡



























(𝑘21 − 𝛼) ∙ (𝑘31 − 𝛼)
(𝛽 − 𝛼) ∙ (𝛾 − 𝛼)
∙ 𝑒−𝛼𝑡 +
(𝑘21 − 𝛽) ∙ (𝑘31 − 𝛽)
(𝛼 − 𝛽) ∙ (𝛾 − 𝛽)
∙ 𝑒−𝛽𝑡 +
(𝑘21 − 𝛾) ∙ (𝑘31 − 𝛾)
(𝛼 − 𝛾) ∙ (𝛽 − 𝛾)
∙ 𝑒−𝛾𝑡] 
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𝑀𝑅𝑇𝑜𝑟𝑎𝑙 = 𝑀𝑅𝑇𝐼𝑉 + 𝑀𝐴𝑇 




































































𝐸 = 𝑆 ∙ 𝐶 
𝐸 = 𝐸𝑜 + 𝑆 ∙ 𝐶 
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(140 − 𝑎𝑔𝑒) ∙ (𝑤𝑒𝑖𝑔ℎ𝑡 𝑖𝑛 𝑘𝑔)
0.815 ∙  𝑆𝑒𝐶𝑟 (𝑚𝑜𝑙/𝐿)
𝑜𝑟 
(140 − 𝑎𝑔𝑒) ∙ (𝑤𝑒𝑖𝑔ℎ𝑡 𝑖𝑛 𝑘𝑔)
72 ∙  𝑆𝑒𝐶𝑟 (𝑚𝑔/𝑑𝐿)
 
For adult women, multiply the above equation by 0.85 
[Weight = ideal weight (for obese person) or actual weight (whichever is lower)] 

















𝐷𝑜𝑠𝑒𝑓𝑎𝑖𝑙𝑢𝑟𝑒 = 𝐷𝑜𝑠𝑒𝑛𝑜𝑟𝑚𝑎𝑙[𝑓 ∙ (𝐾𝐹 − 1) + 1] 
𝑡½𝑓𝑎𝑖𝑙𝑢𝑟𝑒 =
𝑡½𝑛𝑜𝑟𝑚𝑎𝑙
[𝑓 ∙ (𝐾𝐹 − 1) + 1]
 
Digoxin Pharmacokinetics 
𝐶𝐿𝐷𝑖𝑔𝑜𝑥𝑖𝑛 = 1.303 𝐶𝑟𝐶𝐿 + 𝐶𝐿𝑁𝑅 
CLNR = 40mL/min for patients with mild heart failure (NYHA CHF Classes I or II) or 20mL/min for 
patients with severe heart failure (NYHA CHF Classes III or IV) 





𝑘 = 0.00293 ∙ 𝐶𝑟𝐶𝐿 + 0.014 
Body Weight 
𝐵𝑀𝐼 =
𝑇𝑜𝑡𝑎𝑙 𝐵𝑜𝑑𝑦 𝑊𝑒𝑖𝑔ℎ𝑡 (𝑇𝐵𝑊 𝑖𝑛 𝑘𝑔)
[𝐻𝑒𝑖𝑔ℎ𝑡 (𝑚)]2
 






𝐿𝑒𝑎𝑛 𝐵𝑜𝑑𝑦 𝑊𝑒𝑖𝑔ℎ𝑡 (𝐿𝐵𝑊) = (1.10 ∙ 𝑇𝐵𝑊) − (0.0128 ∙ 𝐵𝑀𝐼 ∙ 𝑇𝐵𝑊) 
For females 
𝐿𝑒𝑎𝑛 𝐵𝑜𝑑𝑦 𝑊𝑒𝑖𝑔ℎ𝑡 (𝐿𝐵𝑊) = (1.07 ∙ 𝑇𝐵𝑊) − (0.0148 ∙ 𝐵𝑀𝐼 ∙ 𝑇𝐵𝑊) 
Vd for aminoglycosides in obese patients (TBW >130% IBW) 
𝑉𝑑  = 0.26 ∙ [𝐼𝐵𝑊 + 0.4 ∙ (𝑇𝐵𝑊 − 𝐼𝐵𝑊)] 
Vd for phenytion in obese patients 
𝑉𝑑  = 0.7 ∙ [𝐼𝐵𝑊 + 1.33 ∙ (𝑇𝐵𝑊 − 𝐼𝐵𝑊)] 
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Paediatric Patients (Aminoglycosides) 








𝐵𝑆𝐴 (𝑚2) = 0.024265 ∙ 𝑊𝑒𝑖𝑔ℎ𝑡0.5378(𝑘𝑔) ∙ 𝐻𝑒𝑖𝑔ℎ𝑡0.3964(𝑐𝑚) 
(Haycock et al, 1978) 
Paediatric Patients (Hepatic Function Development) 












Paediatric Patients (Renal Function Development) 





0.0113 ∙ 𝑆𝑒𝐶𝑟 (𝜇𝑚𝑜𝑙/𝐿)
 
k = 0.413 (revised) 
















End of Equations List 
